Abivax Completes Enrollment for Phase 3 Ulcerative Colitis Trials

Abivax SA Sponsored ADR ( (ABVX) ) has shared an update.

On April 29, 2025, Abivax SA announced the completion of enrollment for its Phase 3 ABTECT trials, which are evaluating obefazimod in patients with moderately to severely active ulcerative colitis. The trials successfully enrolled 1,275 participants, surpassing the target by 4%. This milestone is significant for Abivax as it positions the company closer to potentially offering a new therapeutic option for ulcerative colitis patients. Top-line results from the induction trials are expected in Q3 2025, with long-term maintenance data anticipated in Q2 2026, and a New Drug Application submission planned for the second half of 2026, pending successful outcomes.

Spark’s Take on ABVX Stock

According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.

Abivax SA has strong revenue growth but faces challenges with profitability, heavily relying on external financing. The technical indicators show a bearish trend, and the valuation remains unattractive due to negative earnings. The lack of substantial guidance or sentiment from the earnings call provides limited insight into future performance. Overall, the stock is positioned in a challenging environment typical of biotech firms in growth stages.

To see Spark’s full report on ABVX stock, click here.

More about Abivax SA Sponsored ADR

Abivax SA is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, their lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

YTD Price Performance: -0.41%

Average Trading Volume: 208,373

Technical Sentiment Signal: Buy

Current Market Cap: $447.2M

For a thorough assessment of ABVX stock, go to TipRanks’ Stock Analysis page.